TONIX PHARMACEUTICALS HOLDIN (TNXP) Fundamental Analysis & Valuation

NASDAQ:TNXP • US8902608392

Current stock price

15 USD
-0.77 (-4.88%)
At close:
14.9793 USD
-0.02 (-0.14%)
After Hours:

This TNXP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TNXP Profitability Analysis

1.1 Basic Checks

  • In the past year TNXP has reported negative net income.
  • TNXP had a negative operating cash flow in the past year.
  • TNXP had negative earnings in each of the past 5 years.
  • In the past 5 years TNXP always reported negative operating cash flow.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • The Return On Assets of TNXP (-44.75%) is comparable to the rest of the industry.
  • TNXP has a Return On Equity of -50.59%. This is in the better half of the industry: TNXP outperforms 64.22% of its industry peers.
Industry RankSector Rank
ROA -44.75%
ROE -50.59%
ROIC N/A
ROA(3y)-66.7%
ROA(5y)-58.04%
ROE(3y)-84.77%
ROE(5y)-70.59%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • TNXP has a Gross Margin of 49.34%. This is in the better half of the industry: TNXP outperforms 75.05% of its industry peers.
  • The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TNXP Health Analysis

2.1 Basic Checks

  • TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TNXP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TNXP has been increased compared to 5 years ago.
  • There is no outstanding debt for TNXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -0.95, we must say that TNXP is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TNXP (-0.95) is comparable to the rest of the industry.
  • There is no outstanding debt for TNXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.95
ROIC/WACCN/A
WACC8.9%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 7.42 indicates that TNXP has no problem at all paying its short term obligations.
  • The Current ratio of TNXP (7.42) is better than 70.41% of its industry peers.
  • A Quick Ratio of 7.23 indicates that TNXP has no problem at all paying its short term obligations.
  • TNXP has a better Quick ratio (7.23) than 69.44% of its industry peers.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.23
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TNXP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.44% over the past year.
  • Looking at the last year, TNXP shows a very strong growth in Revenue. The Revenue has grown by 29.85%.
EPS 1Y (TTM)99.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.26%
Revenue 1Y (TTM)29.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%108.75%

3.2 Future

  • TNXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.76% yearly.
  • TNXP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 126.50% yearly.
EPS Next Y44.27%
EPS Next 2Y33.38%
EPS Next 3Y22.76%
EPS Next 5YN/A
Revenue Next Year708.37%
Revenue Next 2Y231.62%
Revenue Next 3Y126.5%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -500M -1B -1.5B

More info and screens

Find the best growth stocksShow best growing peers

1

4. TNXP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TNXP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TNXP's earnings are expected to grow with 22.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.38%
EPS Next 3Y22.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TNXP Dividend Analysis

5.1 Amount

  • TNXP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TNXP Fundamentals: All Metrics, Ratios and Statistics

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (3/20/2026, 8:25:30 PM)

After market: 14.9793 -0.02 (-0.14%)

15

-0.77 (-4.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners29.57%
Inst Owner Change49.28%
Ins Owners0.07%
Ins Owner Change0%
Market Cap201.15M
Revenue(TTM)13.11M
Net Income(TTM)-124.02M
Analysts82.5
Price Target67.66 (351.07%)
Short Float %16.45%
Short Ratio5.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.25%
Min EPS beat(2)-22.32%
Max EPS beat(2)1.82%
EPS beat(4)2
Avg EPS beat(4)-6.1%
Min EPS beat(4)-22.32%
Max EPS beat(4)13.8%
EPS beat(8)5
Avg EPS beat(8)-32.16%
EPS beat(12)7
Avg EPS beat(12)-19.12%
EPS beat(16)10
Avg EPS beat(16)-9.21%
Revenue beat(2)2
Avg Revenue beat(2)43.66%
Min Revenue beat(2)4.05%
Max Revenue beat(2)83.27%
Revenue beat(4)2
Avg Revenue beat(4)15.3%
Min Revenue beat(4)-19.5%
Max Revenue beat(4)83.27%
Revenue beat(8)2
Avg Revenue beat(8)-6.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.59%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.35
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-14.27
EYN/A
EPS(NY)-7.95
Fwd EYN/A
FCF(TTM)-7.7
FCFYN/A
OCF(TTM)-7.45
OCFYN/A
SpS0.98
BVpS18.28
TBVpS18.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.75%
ROE -50.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.34%
FCFM N/A
ROA(3y)-66.7%
ROA(5y)-58.04%
ROE(3y)-84.77%
ROE(5y)-70.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.01%
Cap/Sales 25.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.23
Altman-Z -0.95
F-Score5
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)120.84%
Cap/Depr(5y)14966.9%
Cap/Sales(3y)42.84%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.26%
EPS Next Y44.27%
EPS Next 2Y33.38%
EPS Next 3Y22.76%
EPS Next 5YN/A
Revenue 1Y (TTM)29.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%108.75%
Revenue Next Year708.37%
Revenue Next 2Y231.62%
Revenue Next 3Y126.5%
Revenue Next 5YN/A
EBIT growth 1Y-61.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.88%
OCF growth 3YN/A
OCF growth 5YN/A

TONIX PHARMACEUTICALS HOLDIN / TNXP Fundamental Analysis FAQ

What is the fundamental rating for TNXP stock?

ChartMill assigns a fundamental rating of 4 / 10 to TNXP.


What is the valuation status of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

ChartMill assigns a valuation rating of 1 / 10 to TONIX PHARMACEUTICALS HOLDIN (TNXP). This can be considered as Overvalued.


How profitable is TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

TONIX PHARMACEUTICALS HOLDIN (TNXP) has a profitability rating of 1 / 10.